Ipsen announced the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective March 23, 2026. Michelle will serve on the Executive Leadership Team (ELT) and will report directly to Ipsen?s Chief Executive Officer (CEO), David Loew. Michelle joins us from Alltrna, a U.S.-based biotech, where she has served as President and CEO since 2022.
Michelle has spent her 25+ year career in the pharmaceutical industry, starting at Bristol Myers Squibb (BMS) first in the sales and commercial teams in UK at country level and then marketing for the EMEA region within their Oncology division. In 2009 she was appointed Director for Global Market Access for their Oncology & Virology portfolios, back in the U.S. In 2011 she was appointed Global Brand Lead for their Non-Small Cell Lung Cancer (NSCLC) portfolio and in 2014 she became the U.S. Brand Lead for their Reyataz and Evotaz franchises. In 2015 Michelle moved to AstraZeneca to serve as Head of the Immuno-Oncology franchise & Oncology business unit in the U.S. where she oversaw several major product launches.
In 2018 she was appointed Country President for the Nordics & Baltics based in Sweden. In 2020 Michelle came back to the U.S. as Global Franchise Head for Hematology. Shortly after, she moved to Novartis Oncology where she served as Global Franchise Head for Solid Tumors starting in July 2020, before joining Alltrna.
Keira Driansky, EVP and President for North America, is leaving the company to pursue external opportunities.
